Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director | January 02, 2026 | January 07, 2026 |
| BeOne Medicines Ltd.ONC · Entity 2168 | Director | June 11, 2026 | June 15, 2026 |
| Century Therapeutics, Inc.IPSC · Entity 5739 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 19,880 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 7,380 · Balance 19,880 F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. F2: Each RSU represents a contingent right to receive one ordinary share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2036-01-02 | Direct | 14,761 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 14,761 · Balance 14,761 F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
F2: Each RSU represents a contingent right to receive one ordinary share.
F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
BeOne Medicines Ltd.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 73,164 |
Reported balance
After 2026-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 18,980 · Balance 73,164 F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.
Century Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2036-06-11 | Direct | 74,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 74,000 · Balance 74,000 F1: The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 21:08 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 74,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001867172-26-000006 · form4-06122026_090629.xml · derivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:49 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 18,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001867172-26-000007 · wk-form4_1781560162.xml · nonDerivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,164 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy. Read SEC document |
| May 22, 2026 Filed May 27, 2026 21:29 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 212 | $309.51 | $65,617.01 |
DisclosureSEC source: 0001867172-26-000004 · wk-form4_1779917348.xml · nonDerivative · entry 2 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 14,761 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001867172-26-000002 · form4-01062026_080113.xml · derivative · entry 2 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,761 Underlying: Ordinary Shares · 14,761 shares Expires 2036-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 7,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001867172-26-000002 · form4-01062026_080113.xml · nonDerivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,880 F1 · shares: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:25 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001062993-25-011786 · form4.xml · derivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 21, 2025 Filed May 22, 2025 23:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $18.19 | $0.00 |
DisclosureSEC source: 0001651308-25-000088 · wk-form4_1747957486.xml · derivative · entry 2 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,750 Underlying: Ordinary Shares · 22,750 shares Expires 2035-05-20 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 21, 2025 Filed May 22, 2025 23:44 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 10,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000088 · wk-form4_1747957486.xml · nonDerivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,940 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 21:17 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001415889-25-009117 · form4-03272025_090317.xml · derivative · entry 2 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2035-03-25 F3 · derivative.exercise_date: This option will vest in three equal installments on each of March 25, 2026, March 25, 2027 and March 25, 2028. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 21:17 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009117 · form4-03272025_090317.xml · nonDerivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 F1 · shares: Represents a restricted share unit ("RSU") award. The RSUs will vest in three equal installments on each of March 25, 2026, March 25, 2027 and March 25, 2028. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:50 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001062993-24-012903 · form4.xml · derivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:57 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,151 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001651308-24-000059 · wk-form4_1717793831.xml · derivative · entry 2 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,151 Underlying: Ordinary Shares · 34,151 shares Expires 2034-06-04 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:57 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-24-000059 · wk-form4_1717793831.xml · nonDerivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,955 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:22 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001062993-23-014172 · form4.xml · derivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 23:01 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 26,975 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001651308-23-000098 · wf-form4_168730207645417.xml · derivative · entry 2 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,975 Underlying: Ordinary Shares · 26,975 shares Expires 2033-06-14 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 23:01 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 12,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-23-000098 · wf-form4_168730207645417.xml · nonDerivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,614 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,645 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0001651308-22-000106 · wf-form4_165610666171630.xml · derivative · entry 2 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,645 Underlying: Ordinary Shares · 34,645 shares Expires 2032-06-21 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-22-000106 · wf-form4_165610666171630.xml · nonDerivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,692 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:23 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 19,872 | $0.00 Strike: $8.56 | $0.00 |
DisclosureSEC source: 0001062993-22-014657 · form4.xml · derivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 22,581 | $0.00 Strike: $16.22 | $0.00 |
DisclosureSEC source: 0001651308-22-000034 · wf-form4_164625896762526.xml · derivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,581 Underlying: Ordinary Shares · 22,581 shares Expires 2032-02-27 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:31 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantOption (right to buy) · Derivative | 19,872 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000557 · edgar.xml · derivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 17, 2022 or (b) the next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.